Expression of Bcl-2 Family Members in Malignant Pleural Mesothelioma

References

• Antman K, Shemin R, Ryan L, Klegar K, Osteen R, Herman T, et al. Malignant mesothelioma: Prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965–1985. J Clin Oncol 1988; 6: 147–53
   PubMed Web of Science ®Google Scholar
• Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE, Giaccone G. Prognostic factors in patients with pleural mesothelioma: The European Organization for Research and Treatment of Cancer experience. J Clin Oncol 1998; 16: 145–52
   PubMed Web of Science ®Google Scholar
• Herndon JE, Green MR, Chahinian AP, Corson JM, Suzuki Y, Vogelzang NJ. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998; 113: 723–31
   PubMed Web of Science ®Google Scholar
• Edwards JG, Abrams KR, Leverment JN, Spyt TJ, Waller DA, O'Byrne KJ. Prognostic factors for malignant mesothelioma in 142 patients validation of CALGB and EORTC prognostic scoring systems. Thorax 2000; 55: 731–5
   PubMed Web of Science ®Google Scholar
• Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636–44
   PubMed Web of Science ®Google Scholar
• Ramael M, Lemmens G, Eerdekens C, Buysse C, Deblier I, Jacobs W, et al. Immunoreactivity for p53 protein in malignant mesothelioma and non-neoplastic mesothelium. J Pathol 1992; 168: 371–5
   PubMed Web of Science ®Google Scholar
• Mor O, Yaron P, Huszar M, Yellin A, Jakobovitz O, Brok-Simoni F, et al. Absence of p53 mutations in malignant mesothelioma. Am J Resp Cell Mol 1997; 16: 9–13
   PubMed Web of Science ®Google Scholar
• Kirkin V, Joos S, Zornig M. The Role of Bcl-2 family members in tumorigenesis. Acta Bioch Bioph 2004; 1644: 229–49
   PubMed Web of Science ®Google Scholar
• Huang DC, Strasser A. BH3-Only proteins – essential initiators of apoptotic cell death. Cell 2000; 103: 839–42
   PubMed Web of Science ®Google Scholar
• Cory S, Adams JM. The Bcl-2 family: Regulators of the cellular life-or-death switch. Nat Rev Cancer 2002; 2: 647–56
   PubMed Web of Science ®Google Scholar
• Reed JC. Mechanisms of apoptosis avoidance in cancer. Curr Opin Oncol 1999; 11: 68–75
   PubMedGoogle Scholar
• Debatin K-M. Apoptosis pathways in cancer and cancer therapy. Cancer Immunol Immun 2004; 53: 153–9
   PubMed Web of Science ®Google Scholar
• Cawkwell L, Gray S, Murgatroyd H, Sutherland F, Haine L, Longfellow M, et al. Choice of management strategy for colorectal cancer based on a diagnostic immunohistochemical test for defective mismatch repair. Gut 1999; 45: 409–15
   PubMed Web of Science ®Google Scholar
• Berrieman HK, Smith L, O'Kane SL, Campbell A, Lind MJ, Cawkwell L. The Expression of Bcl-2-Family Proteins Differs Between Non-Small Cell Lung Cancer Sub-Types. Cancer 2005; 103: 1415–9
   PubMed Web of Science ®Google Scholar
• Kafiri G, Thomas DM, Shepherd NA, Krausz T, Lane DP, Hall PA. p53 expression is common in malignant mesothelioma. Histopathology 1992; 21: 331–4
   PubMed Web of Science ®Google Scholar
• Segers K, Backhovens H, Singh SK, De Voecht J, Ramael M, Von Broeckhoven C, et al. Immunoreactivity for p53 mutations in human malignant mesotheliomas. Virchows Arch 1995; 427: 431–6
   PubMedGoogle Scholar
• Kitamura F, Araki S, Tanigawa T, Miura H, Akabane H, Iwasaki R. Assessment of mutations of Ha- and Ki-ras oncogenes and the p53 suppressor gene in seven malignant mesothelioma patients exposed to asbestos--PCR-SSCP and sequencing analyses of paraffin-embedded primary tumors. Ind Health 1998; 36: 52–6
   PubMed Web of Science ®Google Scholar
• Kitamura F, Araki S, Suzuki Y, Yokoyama K, Tanigawa T, Iwasaki R. Assessment of the mutations of p53 suppressor gene and Ha- and Ki-ras oncogenes in malignant mesothelioma in relation to asbestos exposure: A study of 12 American patients. Ind Health 2002; 40: 175–81
   PubMedGoogle Scholar
• Segers K, Ramael M, Singh SK, Weyler J, Van Meerbeeck J, Vermeire P, et al. Immunoreactivity for Bcl-2 proteins in malignant mesothelioma and non-neoplastic mesothelium. Virchows Arch 1994; 424: 631–4
   PubMed Web of Science ®Google Scholar
• Soini Y, Kinnula V, Kaarteenaho-Wiik R, Kurttila E, Linnainmaa K, Paakko P. Apoptosis and expression of apoptosis regulating proteins bcl-2, mcl-1, bcl-X and bax in malignant mesothelioma. Clin Cancer Res 1999; 5: 3508–15
   PubMed Web of Science ®Google Scholar
• Lumb PD, Suvarna SK. Metastasis in pleural mesothelioma. Immunohistochemical markers for disseminated disease. Histopathology 2004; 44: 345–52
   PubMed Web of Science ®Google Scholar
• Kaarteenaho-Wiik R, Soini Y, Pollanen R, Paakko P, Kinnula VL. Overexpression of tenascin-C in malignant pleural mesothelioma. Histopathology 2003; 42: 280–91
   Google Scholar